What Limits the Finished Sterility Assurance Level in Equine Chlorhexidine Uterine Lavage Manufacturing?

In equine reproductive medicine, post-breeding persistent endometritis is managed with low-concentration chlorhexidine gluconate lavage fluids that must meet sterile pharmaceutical specifications. The API is controlled against Ph. Eur. 0658 for chlorhexidine digluconate solution, and the diluent is specified as Water for Injections Ph. Eur. 0169. Finished product release includes sterility testing according to Ph. Eur. 2.6.1, bacterial endotoxin testing according to Ph. Eur. 2.6.14, and visual clarity inspection against an illuminated black-white background at 2500 lux. Manufacturing is executed under EU GMP Annex 1 conditions, with aseptic filling in a grade A zone and grade B background; bulk holding time after compounding is limited to 24 h unless the marketing authorisation dossier contains microbial growth data supporting extension. The formulation addition ratio for a 0.05% w/v final solution is 2.5 mL of 20% w/v chlorhexidine gluconate per 1 L of Water for Injections, equivalent to 500 mg chlorhexidine gluconate per litre. Mixing is performed in a 316L stainless-steel vessel with internal surface roughness Ra ≤ 0.8 μm at 20–25 °C; the concentrate is introduced by a metered pump below the liquid surface under low-shear stirring at 60–120 rpm to limit foam entrainment. Because chlorhexidine digluconate is cationic, the manufacturing line excludes anionic surfactants, sodium alginate, and natural rubber closures; product-contact surfaces are silicone or fluoropolymer-lined. The bulk solution is passed through a 0.22 μm polyethersulfone membrane with an upstream prefilter, and the membrane integrity is challenged under ASTM F838-20 before filling. Terminal finished product types are sterile 500 mL and 1 L low-density polyethylene bottles with tamper-evident closures for equine intrauterine lavage kits. Despite the term injection appearing in the API form listing, chlorhexidine is not authorized for parenteral injection in veterinary pharmacopoeias because systemic exposure is associated with ototoxicity and neurotoxicity; downstream use is confined to topical, lavage, and non-systemic cavity treatments.

Bovine postpartum uterine flushing with chlorhexidine gluconate at dilutions of 0.05% w/v to 0.10% w/v is encountered in herd-health programmes where retained fetal membranes or early metritis require non-antibiotic lavage support. The addition ratio spans 2.5 mL to 5.0 mL of 20% w/v chlorhexidine gluconate per 1 L of Water for Injections Ph. Eur. 0169; the upper concentration is used only when the veterinary medicinal product authorisation or prescription explicitly specifies it because higher concentrations are associated with greater mucosal irritation potential. Compliance for this product category falls under the Veterinary Medicinal Products Regulation (EU) 2019/6 and applicable national formularies; release testing includes Ph. Eur. 2.6.1 sterility, Ph. Eur. 2.6.14 endotoxin, and pH 5.5–7.0. In downstream production, a 5000 L bulk vessel is used for dilution, and filling is performed on a blow-fill-seal line or rotary piston filler in a grade A unidirectional-airflow zone. The concentrated chlorhexidine gluconate is tempered to 20–25 °C for 24 h before metering because viscosity differences observed at low storage temperatures produce batch-to-batch fill-weight variation. No anionic additives are permitted because chlorhexidine forms insoluble complexes with sodium lauryl sulfate and carboxymethylcellulose; precipitation is evaluated at 5 °C and 40 °C during formulation development. The finished product is delivered as 1 L, 2 L, and 5 L collapsible bags or semi-rigid bottles with administration ports, each port being leak-tested after capping.

Compression Parameters and Ionic Incompatibilities in Chlorhexidine Dihydrochloride Intrauterine Tablets

Chlorhexidine dihydrochloride is processed into low-dose intrauterine tablet blends intended for bovine reproductive tract antisepsis. The API conforms to Ph. Eur. 0657 and is supplied as a milled powder with particle size D90 < 100 μm to support content uniformity in low-dose direct-compression formulations. A development batch targeting a 0.5 g tablet that delivers 20 mg chlorhexidine dihydrochloride corresponds to a formulation addition ratio of 4.0% w/w. Excipients screened in preformulation include microcrystalline cellulose, lactose monohydrate, povidone K30, and sodium starch glycolate; however, sodium starch glycolate is replaced by crospovidone in formulations where ionic interaction with the cationic biguanide retards disintegration. The blend is mixed for 15 min in a bin blender at 23 rpm, then lubricated with 0.5% w/w magnesium stearate for 3 min. Compression is performed on a rotary tablet press fitted with 10 mm flat-faced bevel-edge tooling at a main compression force of 10–15 kN; target hardness is 40–70 N, and friability is controlled below 0.8% per Ph. Eur. 2.9.7. Disintegration is evaluated according to Ph. Eur. 2.9.1 in 500 mL water at 37 ± 2 °C; published compendial limits specific to intrauterine tablets are limited, so the disintegration endpoint must be justified in the marketing authorisation dossier. Dissolution release testing, where required, uses Ph. Eur. 2.9.3 apparatus 2 at 50 rpm. The terminal product is a 0.5 g intrauterine tablet packed in aluminium-aluminium blister strips or single-dose sachets with desiccant. Production-scale data for chlorhexidine intrauterine tablet compression remains limited, so the stated parameters are development specifications rather than universal batch records.

Dairy mastitis control uses chlorhexidine gluconate as a post-milking teat disinfectant. A concentrated premix at 5.0% w/w chlorhexidine gluconate is manufactured for farm dilution at 1 part concentrate to 9 parts potable water, yielding a ready-to-use concentration of 0.5% w/w. The product must demonstrate bactericidal activity in the veterinary field under EN 1656:2019 and, where teat skin conditioning claims are made, carrier test performance under EN 16437:2014. Production begins with a rotor-stator high-shear step at 3000 rpm to disperse a nonionic surfactant and a cellulosic thickener, followed by low-shear anchor mixing at 30 rpm after addition of sorbitol and glycerol. The pH is adjusted with lactic acid to 5.5–6.5; citric acid is avoided in concentrates stored or transported in carbon steel because of corrosion risk. Temperature is maintained at 20–25 °C because chlorhexidine gluconate viscosity rises sharply below 15 °C, and metered farm dosing pumps show increased deviation at lower temperatures. A 1000 L stainless-steel mixing vessel is used, and the batch is screened through a 500 μm filter before filling into 20 L HDPE jerrycans or 200 L drums. Terminal product types include ready-to-use teat dip, dip cup refills, and farm concentrate used with automated dosing pumps under Regulation (EU) 528/2012 where national biocide authorisation applies.

Small animal periodontal care products containing chlorhexidine gluconate are formulated as mucoadhesive gels for oral application in dogs and cats; the active concentration is commonly 0.5% w/w chlorhexidine gluconate, with hydroxyethylcellulose as the gel matrix at 2.0% w/w. The formulation process hydrates hydroxyethylcellulose in purified water and glycerol at 60 °C, then cools the gel base to 25 °C before adding a 20% w/v chlorhexidine gluconate stock solution under vacuum. Deaeration is carried out in a planetary vacuum mixer at −0.08 MPa for 30 min; residual air content is measured by pycnometry because entrapped air destabilises the gel and creates fill-weight variation during tube filling. Release testing includes microbial quality according to Ph. Eur. 5.1.4, assay by liquid chromatography referenced to Ph. Eur. 0658, and pH 5.5–6.5. The finished product is filled into 15 g and 30 g aluminium tubes with polypropylene caps; tube filling machines are set to reject product below 95% of labelled fill weight. The preparation is not intended for systemic use, and accidental ingestion safety data in target species are compiled under VICH GL18 stability and safety frameworks. Production lines using anionic thickeners such as carbomer fail viscosity specification because chlorhexidine forms insoluble carboxylate complexes; nonionic cellulose grades are substituted to maintain rheological stability.

When a 4.0% w/v Chlorhexidine Gluconate Surgical Scrub Is Formulated Without Anionic Surfactants

Preoperative skin antisepsis in veterinary surgery uses an aqueous scrub formulation at 4.0% w/v chlorhexidine gluconate. The addition ratio in manufacture is 200 mL of 20% w/v chlorhexidine gluconate per 1 L final volume, with the balance composed of purified water, nonionic surfactants, glycerol, and a poloxamer thickener to a target viscosity of 1200–2000 mPa·s at 25 °C. The product is validated under EN 12791 for surgical hand antisepsis and EN 13727 for bactericidal activity; challenge testing is conducted with target species field isolates because veterinary performance differs from human reference strains. Mixing is performed in a 316L vessel with an anchor stirrer at 40 rpm; the API is added after surfactant dispersion to avoid local gel formation and pump cavitation. The pH is maintained at 5.5–6.5 with sodium hydroxide; hydrochloric acid is avoided in chloride-sensitive stainless-steel systems. Because the formulation is aqueous and non-sterile, microbial limits follow Ph. Eur. 5.1.4, and preservation challenge testing is conducted against Pseudomonas aeruginosa and Staphylococcus pseudintermedius. The terminal product is a 500 mL HDPE bottle with pump dispenser or a 1 L refill pack for equine and small animal clinics. Chlorhexidine is not formulated into parenteral injections; the finished surgical scrub is strictly topical, and the label states external use only.